|
James Liu
Human Capital Advisor |
James Liu is a Human Capital Advisor for the SES Group, based in Beijing and responsible for SES’s Greater China Life Sciences Human Capital Advisory activities.
James has had a long and distinguished career in the Greater China pharmaceuticals and healthcare sector, dating from 1976, when he started his career with Boeringher Ingelheim In Taiwan, until 2008, when he retired from Novartis, having led and grown their significant China business from 1999 onwards. Prior to that, James rose through sales & marketing to general management roles at Eli Lilley, Warner Lambert, Wyeth Ayerst, Sandoz, and then Novartis in Taiwan.
He has also held many industry leadership roles, most recently Chairman and, now, Honorary Chairman of RDPAC (China Association of Enterprises with Foreign Investment, Research & Development based Pharmaceutical Association Committee), from 2005 to the present; and Vice President of China Association of Enterprises with Foreign Investment (CAEFI ).
Previously he had also served as the Chairman of IPRMA (Int’l R&D Pharma. Association ) in Taiwan. He is also Visiting Professor for the Master Degree Program in Int’l Pharmaceutical Engineering Management, Peking University.
James Liu can be reached at jliu@sesasia.com.
James has had a long and distinguished career in the Greater China pharmaceuticals and healthcare sector, dating from 1976, when he started his career with Boeringher Ingelheim In Taiwan, until 2008, when he retired from Novartis, having led and grown their significant China business from 1999 onwards. Prior to that, James rose through sales & marketing to general management roles at Eli Lilley, Warner Lambert, Wyeth Ayerst, Sandoz, and then Novartis in Taiwan.
He has also held many industry leadership roles, most recently Chairman and, now, Honorary Chairman of RDPAC (China Association of Enterprises with Foreign Investment, Research & Development based Pharmaceutical Association Committee), from 2005 to the present; and Vice President of China Association of Enterprises with Foreign Investment (CAEFI ).
Previously he had also served as the Chairman of IPRMA (Int’l R&D Pharma. Association ) in Taiwan. He is also Visiting Professor for the Master Degree Program in Int’l Pharmaceutical Engineering Management, Peking University.
James Liu can be reached at jliu@sesasia.com.
